Brokerages forecast that OptiNose Inc (NASDAQ:OPTN) will post sales of $12.45 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for OptiNose’s earnings, with the lowest sales estimate coming in at $12.40 million and the highest estimate coming in at $12.50 million. OptiNose reported sales of $3.02 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 312.3%. The firm is scheduled to report its next earnings results on Wednesday, March 4th.
According to Zacks, analysts expect that OptiNose will report full year sales of $35.98 million for the current financial year, with estimates ranging from $35.95 million to $36.00 million. For the next fiscal year, analysts forecast that the company will report sales of $86.75 million, with estimates ranging from $83.10 million to $90.39 million. Zacks’ sales averages are an average based on a survey of analysts that follow OptiNose.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.69). OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. The company had revenue of $12.40 million for the quarter, compared to analysts’ expectations of $8.56 million.
NASDAQ:OPTN traded down $0.11 during trading hours on Friday, hitting $9.34. 260,563 shares of the stock traded hands, compared to its average volume of 421,316. The firm has a 50 day moving average price of $9.18 and a 200 day moving average price of $7.42. The company has a current ratio of 4.81, a quick ratio of 4.66 and a debt-to-equity ratio of 1.67. OptiNose has a fifty-two week low of $4.44 and a fifty-two week high of $11.66. The firm has a market cap of $392.95 million, a price-to-earnings ratio of -3.49 and a beta of 0.75.
In related news, Director Joseph C. Scodari purchased 6,100 shares of the stock in a transaction dated Friday, December 6th. The shares were acquired at an average cost of $8.64 per share, for a total transaction of $52,704.00. Also, major shareholder Avista Capital Partners Ii Gp, sold 1,250,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.17, for a total transaction of $11,462,500.00. The disclosure for this sale can be found here. 44.30% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the company. Tamarack Advisers LP purchased a new position in shares of OptiNose during the 3rd quarter valued at $4,725,000. Massachusetts Financial Services Co. MA boosted its holdings in OptiNose by 18.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,033,499 shares of the company’s stock worth $7,234,000 after purchasing an additional 160,664 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in OptiNose in the third quarter worth $117,000. BlackRock Inc. boosted its holdings in OptiNose by 15.9% in the second quarter. BlackRock Inc. now owns 1,918,914 shares of the company’s stock worth $13,586,000 after purchasing an additional 263,667 shares in the last quarter. Finally, Wildcat Capital Management LLC bought a new stake in OptiNose in the third quarter worth $3,628,000. Institutional investors and hedge funds own 68.31% of the company’s stock.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Read More: What is a bull market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.